NK

Nandlal Kumawat

Active Director Designated Partner DIN 07853175
DIN 07853175 First appointment Jul 2017 Primary industry Business Services
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2017
Shareholding value β€’β€’β€’β€’ Premium profile

About Nandlal Kumawat

Data last updated:

Nandlal Kumawat is a Designated Partner at Medismith Pharmaceuticals Llp (since 2017). The company operates in Business Services.

DIN 07853175
Primary Designation Designated Partner
Industry Business Services
First Appointment 03 Jul 2017
Oldest Company Age 9 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner03 Jul 20172017Active

Board colleagues of Nandlal Kumawat

NameDINCompanyDesignation
Ashish Swarnkar07853152Medismith Pharmaceuticals LlpDesignated Partner
Manjula Swarnkar07853167Medismith Pharmaceuticals LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Medismith Pharmaceuticals Llp
Premium access

Shareholding and investment profile for Nandlal Kumawat

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nandlal Kumawat

Nandlal Kumawat currently holds 1 directorship: Medismith Pharmaceuticals Llp (Designated Partner, since 03 Jul 2017).

Nandlal Kumawat was first appointed on 03 Jul 2017 as Designated Partner at Medismith Pharmaceuticals Llp.

The current boards of Nandlal Kumawat's companies include Ashish Swarnkar (Medismith Pharmaceuticals Llp), Manjula Swarnkar (Medismith Pharmaceuticals Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available